bioAffinity Q1 2026 CyPath Lung unit sales surge 146% YoY, beat projections

bioAffinity Technologies, Inc.

Q1 2026 CyPath Lung unit sales up 146% YoY, exceeding internal projections on accelerating physician adoption.
Full-year 2025 CyPath Lung revenue rose 87% YoY, units sold up 99% vs 2024.
Addressable U.S. market estimated at $3.58 billion; capturing 10% would represent $358M in sales.
Company advancing large-scale clinical study and R&D pipeline for asthma/COPD diagnostics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.